Bocio y enfermedad nodular

  1. Tasende Fernández, C. 1
  2. Rodríguez Troyano, M.J. 1
  3. Lallena Pérez, S. 1
  4. Álvarez Hernández, J. 1
  1. 1 Sección de Endocrinología y Nutrición, Hospital Universitario Principe de Asturias, Universidad de Alcala, Alcalá de Henares, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2020

Título del ejemplar: Enfermedades endocrinológicas y metabólicas (I)Patología tiroidea

Serie: 13

Número: 13

Páginas: 709-717

Tipo: Artículo

DOI: 10.1016/J.MED.2020.07.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

El bocio y la enfermedad nodular tiroidea son enfermedades generalmente benignas, con una alta prevalencia en la población general. Su mecanismo de desarrollo es desconocido, aunque parecen implicados distintos factores de tipo genético, demográfico (déficit de yodo) y ambiental. El objetivo de la valoración clínica en estos pacientes es principalmente excluir el cáncer de tiroides y, en segundo lugar, valorar la función tiroidea y si existe clínica compresiva por afectación de estructuras anatómicas vecinas. En la evaluación de estas patologías, se realizará una historia clínica y una exploración física detalladas. Para valorar su funcionalidad, se debe solicitar como prueba de laboratorio la TSH y como prueba de imagen, fundamentalmente, la ecografía tiroidea que nos dará la información necesaria para valorar la necesidad de realizar un estudio citológico. Los estudios moleculares pueden estar indicados en pacientes seleccionados. Dependiendo de las características clínicas y ecográficas y/o del resultado citológico, se estratifica a los pacientes en función de su riesgo de malignidad y la mejor opción terapéutica que va desde la observación periódica al manejo quirúrgico.

Referencias bibliográficas

  • Maravall FJ, Gómez-Arnáiz N, Gumá A, Abós R, Soler J, Gómez JM. Reference values of thyroid volume in a healthy, non-iodine-deficient Spanish population. Horm Metab Res. 2004;36(9):645-9.
  • Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologists, Associa-zione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and mana-gement of thyroid nodules. Endocr Pract. 2010;16Suppl1:1-43.
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Manage-ment Guidelines for Adult Patients with Thyroid Nodules and Di-fferentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentieted Thyroid Cancer. Thyroid. 2016;26(1):1-133.
  • Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham Sur-vey. Clin Endocrinol (Oxf). 1977;7:481-93.
  • Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007;36:707-35.
  • Acar T, Ozbek SS, Acar S. Incidentally discovered thyroid nodules: fre-quency in an adult population during Doppler ultrasonographic evalua-tion of cervical vessels. Endocrine. 2014;45(1):73-8.
  • Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Prac Res Clin Endocrinol Metab. 2008;901-11.
  • Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodu-lar goiter: current status and future perspectives. Endocr Res. 2003;24: 102-32.
  • Wang C, Crapo LM. The epidemiology of thyroid disease and implica-tions for screening. Endocrinol Metab Clin North Am. 1997;26:189-218.
  • Rago T, Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22(6):913-28.
  • Smith-Bindman R, Lebda P, Feldstein VA, Sellami D, Goldstein RB, Bra-sic N, et al. Risk of thyroid cáncer based on thyroid ultrasound imaging characteristics: results of a population based study. JAMA Intern Med 2013;173:1788-96.
  • Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab. 2013;98:564-70.
  • Thyroid disease: assessment and management. National Institute for Health and Care Excellence (NICE). [Consultado 20 de november de 2019]. Disponible en: https://www.nice.org.uk/guidance/ng145/ documents/draft-guideline.
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Manage-ment Guidelines for Adult Patients with Thyroid Nodules and Di-fferentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentieted Thyroid Cancer. Thyroid. 2016;26(1):1-133.
  • Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000; 29:187-203.
  • Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005;237:794-800.
  • Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endo-crinol Metab. 2012;26(1):83-96.
  • Russ G, Leboulleux S, Leenhardt L, Hegedüs L. Thyroid incidentalomas: epidemiology, risk stratification with ultrasound and workup. Eur Thyroid J. 2014;3:154-63.
  • Brander AE, Viikinkoski VP, Nickels JI, Kivisaari LM. Importance of thyroid abnormalities detected at US screening: a 5-year follow-up. Ra-diology. 2000;215:801-6.
  • Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22:918-25.
  • Agrawal K, Weaver J, Ngu R, Krishnamurthy Mohan H. Clinical signifi-cance of patterns of incidental thyroid uptake at (18)F-FDG PET/CT. Clin Radiol. 2015;70(5):536-43.
  • Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3(4):286-95.
  • Carlé A, Krejbjerg A, Laurberg P. Epidemiology of nodular goitre. In-fluence of iodine intake. Best Pract Res Clin Endocrinol Metab. 2014; 28(4):465-79.
  • Knudsen N, Brix TH. Genetic and non-iodine-related factors in the ae-tiology of nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014; 28(4):495-506.
  • Derwahl M, Studer H. Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabe-tes. 2001;109(5):250-60.
  • Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: a review. JAMA. 2018;319(9):914-924.
  • Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid can-cer. N Engl J Med. 2016;375(11):1054-67.
  • Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. Endocr Pract. 2017;23(8):979-88.
  • Banks CA, Ayers CM, Hornig JD, Lentsch EJ, Day TA, Nguyen SA, et al. Thyroid disease and compressive symptoms. Laryngoscope. 2012;122(1): 13-6.
  • Durante C, Costante G,LucisanoG, Bruno R, Meringolo D, Pa-ciaroni A. The natural history of benig thyroid nodules. JAMA. 2015; 313(9):926-35.
  • Tonacchera M, Pinchera A, Vitti P. Assessment of nodular goiter. Best Pract Res Clin Endocrinol Metab. 2010;24(1):51-61.
  • Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3): 809-14.
  • Moon W-J, Baek JH, Jung SL, Kim DW, Kim EK, Kim JY, et al. Ultra-sonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol. 2011;12(1): 1-14.
  • Bonavita JA, Mayo J, Babb J, Bennett G, Oweity T, Macari M, et al. Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR Am J Roentgenol. 2009;193(1): 207-13.
  • Virmani V, Hammond I. Sonographic patterns of benign thyroid nodules: verification at our institution. AJR Am J Roentgenol. 2011;196(4): 891-5.
  • Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, et al. American Association of Clinical Endocrinologists, Ameri-can College of Endocrinology, and Associazione Medici Endocrino-logi Medical Guidelines for Clinical Practice for Diagnosis and Ma-nagement of thyroid nodules --2016 UpDate. Endocr Pract. 2016; 22(5):622-39.
  • Shin JH, Baek JH, Chung J, Ha EJ, Kim J, Lee YH, et al. Ultraso-nography diagnosis and imaging-based management of thyroid no-dules: revised korean society of thyroid radiology consensus state-ment and recommendations. Korean J Radiol. 2016;17(3):370-95.
  • Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European thyroid association guidelines for ultrasound ma-lignancy risk stratification of thyroid nodules in adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-37.
  • Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Ra-diol. 2017;14(5):587-95.
  • Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, et al. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the «right» TIRADS. J Clin Endocrinol Metab. 2019;104(1):95-102.
  • Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. J Am Soc of Cytopathology. 2017;6(6):217-22.
Fuente de los datos: Dialnet